journal
MENU ▼
Read by QxMD icon Read
search

Lancet Haematology

journal
https://www.readbyqxmd.com/read/30389037/moderate-intensity-endurance-exercise-training-in-patients-with-sickle-cell-disease-without-severe-chronic-complications-exdre-an-open-label-randomised-controlled-trial
#1
Barnabas Gellen, Laurent A Messonnier, Frédéric Galactéros, Etienne Audureau, Angèle N Merlet, Thomas Rupp, Sandrine Peyrot, Cyril Martin, Léonard Féasson, Pablo Bartolucci
BACKGROUND: Exercise could be a triggering factor for vaso-occlusive crises in patients with sickle-cell disease. We aimed to investigate whether a patient-adapted training programme of moderate endurance exercise could be safe and beneficial for patients with sickle-cell disease. METHODS: We did a multicentre, prospective, open-label, randomised controlled trial at four university hospitals in France. Eligible patients were older than 18 years, with an HbSS or S/β0 -thalassaemia genotype, and with no severe chronic complications...
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30389036/efficacy-pharmacokinetics-and-safety-of-the-biosimilar-ct-p10-in-comparison-with-rituximab-in-patients-with-previously-untreated-low-tumour-burden-follicular-lymphoma-a-randomised-double-blind-parallel-group-phase-3-trial
#2
Michinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, Hideyuki Nakazawa, Junji Suzumiya, Gayane Tumyan, Jin Seok Kim, Anne Lennard, José Mariz, Nikolai Ilyin, Wojciech Jurczak, Aurelio Lopez Martinez, Olga Samoilova, Edvard Zhavrid, Eduardo Yañez Ruiz, Marek Trneny, Leslie Popplewell, Bertrand Coiffier, Christian Buske, Won-Seog Kim, Sang Joon Lee, Sung Young Lee, Yun Ju Bae, Larry W Kwak
BACKGROUND: Studies in patients with rheumatoid arthritis and advanced follicular lymphoma have shown that CT-P10, a rituximab biosimilar, has equivalent or non-inferior efficacy and pharmacokinetics to rituximab. We aimed to assess the therapeutic equivalence of single-agent CT-P10 and rituximab in patients with newly diagnosed low-tumour burden follicular lymphoma. METHODS: In this ongoing, randomised, double-blind, parallel-group, active-controlled, phase 3 trial, adult patients (≥18 years) with stage II-IV low-tumour-burden follicular lymphoma were randomly assigned (1:1) using an interactive web or voice response system stratified by region, stage, and age to CT-P10 or US-sourced rituximab...
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30389035/fludarabine-with-a-higher-versus-lower-dose-of-myeloablative-timed-sequential-busulfan-in-older-patients-and-patients-with-comorbidities-an-open-label-non-stratified-randomised-phase-2-trial
#3
Uday R Popat, Rohtesh S Mehta, Roland Bassett, Julianne Chen, Benigno C Valdez, Jitesh Kawedia, Sairah Ahmed, Amin M Alousi, Paolo Anderlini, Geath Al-Atrash, Qaiser Bashir, Stefan O Ciurea, Chitra M Hosing, Jin S Im, Roy Jones, Partow Kebriaei, Issa Khouri, David Marin, Yago Nieto, Amanda Olson, Betul Oran, Simrit Parmar, Katayoun Rezvani, Muzaffar H Qazilbash, Nina Shah, Samer A Srour, Elizabeth J Shpall, Richard E Champlin, Borje S Andersson
BACKGROUND: Haemopoietic stem-cell transplantation (HCT) conditioning regimens that can reduce risk of relapse without increasing non-relapse mortality are needed. We aimed to test the safety of timed-sequential delivery of low-dose versus high-dose myeloablative busulfan in older patients and patients with comorbidities. METHODS: This non-stratified, open-label, randomised phase 2 trial was done at The University of Texas MD Anderson Cancer Center (Houston, TX, USA)...
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30389034/outcomes-after-r-chop-in-patients-with-newly-diagnosed-advanced-follicular-lymphoma-a-10-year-follow-up-analysis-of-the-jcog0203-trial
#4
Takashi Watanabe, Kensei Tobinai, Masashi Wakabayashi, Yasuo Morishima, Hirofumi Kobayashi, Tomohiro Kinoshita, Takayo Suzuki, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Masafumi Taniwaki, Naokuni Uike, Tadashi Yoshino, Sigeru Nawano, Takashi Terauchi, Tomomitsu Hotta, Hirokazu Nagai, Kunihiro Tsukasaki
BACKGROUND: Standard treatment for untreated advanced-stage follicular lymphoma is rituximab plus chemotherapy. The incidence of histological transformation of follicular lymphoma has been reported only in heterogeneously treated populations and rarely with long-term follow-up. Additionally, the incidence of secondary malignancies after treatment, without high-dose therapy for follicular lymphoma, is largely unknown. The aim of our study was to assess progression-free survival, overall survival, incidence of secondary malignancies, and incidence of histological transformation in a 10-year follow-up analysis of the JCOG0203 trial...
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30389033/exercise-training-a-prescription-for-sickle-cell-disease
#5
Gregory J Kato
No abstract text is available yet for this article.
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30389032/biosimilars-when-a-negative-study-can-be-positive
#6
Brian K Link
No abstract text is available yet for this article.
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30389031/is-pharmacokinetic-guidance-a-must-in-busulfan-regimens
#7
Yoshinobu Kanda
No abstract text is available yet for this article.
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30389030/histological-transformation-and-secondary-malignancies-in-follicular-lymphoma
#8
Umberto Vitolo, Annalisa Chiappella
No abstract text is available yet for this article.
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30389029/embracing-the-complexity-in-cancer-therapy
#9
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30314712/individually-shortened-duration-versus-standard-duration-of-elastic-compression-therapy-for-prevention-of-post-thrombotic-syndrome-a-cost-effectiveness-analysis
#10
Elham E Amin, Arina J Ten Cate-Hoek, Annemieke C Bouman, Karina Meijer, Lidwine Tick, Saskia Middeldorp, Guy Mostard, Marije Ten Wolde, Simone van den Heiligenberg, Sanne van Wissen, Marlene van de Poel, Sabina Villalta, Erik Serné, Hans Martin Otten, Edith Klappe, Paolo Prandoni, Martin H Prins, Hugo Ten Cate, Manuela A Joore
BACKGROUND: The IDEAL DVT study showed that it was safe to shorten the duration of elastic compression therapy on an individualised basis after deep vein thrombosis for prevention of post-thrombotic syndrome. In this study, we assessed the cost-effectiveness of this strategy. METHODS: IDEAL DVT was a multicentre, randomised, non-inferiority trial that included patients with acute proximal deep vein thrombosis of the leg. After 6 months of elastic compression therapy, patients were randomly assigned (1:1) to the standard 2 years of elastic stocking compression therapy or shortened duration of compression therapy based on the patient's Villalta score...
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30314711/elastic-compression-therapy-to-prevent-post-thrombotic-syndrome
#11
Nicos Labropoulos
No abstract text is available yet for this article.
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29907552/beyond-maximum-grade-modernising-the-assessment-and-reporting-of-adverse-events-in-haematological-malignancies
#12
REVIEW
Gita Thanarajasingam, Lori M Minasian, Frederic Baron, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, John Gribben, Mary Horowitz, S Percy Ivy, Caron A Jacobson, Armand Keating, Paul G Kluetz, Aviva Krauss, Yok Lam Kwong, Richard F Little, Francois-Xavier Mahon, Matthew J Matasar, María-Victoria Mateos, Kristen McCullough, Robert S Miller, Mohamad Mohty, Philippe Moreau, Lindsay M Morton, Sumimasa Nagai, Simon Rule, Jeff Sloan, Pieter Sonneveld, Carrie A Thompson, Kyriaki Tzogani, Flora E van Leeuwen, Galina Velikova, Diego Villa, John R Wingard, Sophie Wintrich, John F Seymour, Thomas M Habermann
Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Although cure rates for aggressive malignancies have increased, nowhere has progress been more impactful than in the management of typically incurable forms of haematological cancer. Population-based data have shown that 5-year survival for patients with chronic myelogenous and chronic lymphocytic leukaemia, indolent B-cell lymphomas, and multiple myeloma has improved markedly...
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29907551/the-need-to-assess-financial-adverse-events
#13
Loretta J Nastoupil, Vinay Prasad, Christopher R Flowers
No abstract text is available yet for this article.
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29907550/changing-views-on-adverse-event-reporting
#14
Beatriz Flores, Sigrid Klaar, Daniel J O'Connor
No abstract text is available yet for this article.
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29907549/real-world-evidence-in-safety-assessment-of-new-treatments
#15
Karin E Smedby, Sandra Eloranta
No abstract text is available yet for this article.
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29907548/the-cost-of-cure
#16
Kjeld Schmiegelow, Thomas Leth Frandsen
No abstract text is available yet for this article.
November 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30290905/thalidomide-before-and-after-autologous-stem-cell-transplantation-in-recently-diagnosed-multiple-myeloma-hovon-50-long-term-results-from-the-phase-3-randomised-controlled-trial
#17
Niels Wcj van de Donk, Bronno van der Holt, Monique C Minnema, Edo Vellenga, Sandra Croockewit, Marie José Kersten, Peter A von dem Borne, Paula Ypma, Ron Schaafsma, Okke de Weerdt, Saskia K Klein, Michel Delforge, Mark-David Levin, Gerard M Bos, Kon-Siong G Jie, Harm Sinnige, Jules Llm Coenen, Esther G de Waal, Sonja Zweegman, Pieter Sonneveld, Henk M Lokhorst
BACKGROUND: In patients with recently diagnosed multiple myeloma, the HOVON-50 phase 3 trial showed improved event-free survival for thalidomide-containing induction and maintenance regimens (in conjunction with high-dose melphalan and autologous stem cell transplantation [auto-SCT]) after a median of 52 months of follow-up, by comparison with regimens containing classical cytotoxic drugs. In this follow-up analysis, we aimed to determine the long-term effects of thalidomide in induction and maintenance therapy in multiple myeloma...
October 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30290904/passive-transfer-of-anti-hbc-after-intravenous-immunoglobulin-administration-in-patients-with-cancer-a-retrospective-chart-review
#18
Huifang Lu, Anna S Lok, Carla L Warneke, Sairah Ahmed, Harrys A Torres, Fernando Martinez, Maria E Suarez-Almazor, Jessica T Foreman, Alessandra Ferrajoli, Jessica P Hwang
BACKGROUND: Patients previously infected with hepatitis B virus (HBV; indicated by positivity for anti-HBc) can experience HBV reactivation during cancer chemotherapy. Intravenous immunoglobulin infusion, which is frequently used in supportive care, might facilitate passive transfer of anti-HBc. We aimed to estimate the probability of passive transfer of anti-HBc after intravenous immunoglobulin infusion in patients with cancer. METHODS: We reviewed institutional databases to identify adult patients who received outpatient chemotherapy between Jan 1, 2004, and Dec 31, 2011, at the University of Texas MD Anderson Cancer Center, Houston, TX, USA...
October 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30290903/intensive-treatment-strategies-in-advanced-stage-hodgkin-s-lymphoma-hd9-and-hd12-analysis-of-long-term-survival-in-two-randomised-trials
#19
Bastian von Tresckow, Stefanie Kreissl, Helen Goergen, Paul J Bröckelmann, Thomas Pabst, Michael Fridrik, Mathias Rummel, Wolfram Jung, Julia Thiemer, Stephanie Sasse, Carolin Bürkle, Christian Baues, Volker Diehl, Andreas Engert, Peter Borchmann
BACKGROUND: Although intensified chemotherapy regimens have improved tumour control and survival in advanced-stage Hodgkin's lymphoma, data on the long-term sequelae are scarce. We did preplanned follow-up analyses of the German Hodgkin Study Group (GHSG) trials HD9 and HD12 to assess whether the primary results of these trials-which had shown that intensive initial therapy in advanced-stage Hodgkin's lymphoma has a beneficial effect on treatment outcomes-would continue with longer follow-up...
October 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30290902/brentuximab-vedotin-for-paediatric-relapsed-or-refractory-hodgkin-s-lymphoma-and-anaplastic-large-cell-lymphoma-a-multicentre-open-label-phase-1-2-study
#20
Franco Locatelli, Christine Mauz-Koerholz, Kathleen Neville, Anna Llort, Auke Beishuizen, Stephen Daw, Marta Pillon, Nathalie Aladjidi, Thomas Klingebiel, Judith Landman-Parker, Aurora Medina-Sanson, Keith August, Jessica Sachs, Kristen Hoffman, Judith Kinley, Sam Song, Gregory Song, Stephen Zhang, Ajit Suri, Lia Gore
BACKGROUND: Despite remarkable progress in the treatment of newly-diagnosed classical Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, treatment of relapsed or refractory disease remains challenging. The aims of this study were to assess the safety, tolerability, recommended phase 2 dose, and efficacy of brentuximab vedotin in paediatric patients with relapsed or refractory Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. METHODS: This open-label, dose-escalation phase 1/2 study was done at 12 centres across eight countries (France, Germany, Italy, Mexico, The Netherlands, Spain, UK, and USA)...
October 2018: Lancet Haematology
journal
journal
49595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"